A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of XEN1101 as an Adjunctive Therapy in the Treatment of Primary Generalized Tonic-Clonic Seizures (P11-1.012)

Antonio Gil-Nagel,Jenny Qian,Elinor Ben-Menachem,Gregory Beatch,W Lafrance,Christopher Kenney,Cynthia Harden,David Vossler

doi:10.1212/wnl.0000000000203311

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of XEN1101 as an Adjunctive Therapy in the Treatment of Primary Generalized Tonic-Clonic Seizures (P11-1.012)

Antonio Gil-Nagel, Jenny Qian + Show 6 more

https://doi.org/10.1212/wnl.0000000000203311

Copy DOI

Export

Save

Cite

Journal: Neurology

Publication Date: Apr 25, 2023

Affiliation: Hospital Ruber Internacional, Xenon Pharmaceuticals (Canada), University of Gothenburg, Providence College, Santa Clara Valley Medical Center

#Primary Generalized Tonic-clonic Seizures #Received Research Support #Scientific Advisory #Patient Global Impression Of Change #Potassium Channel Opener #Scientific Data #Pharmaceuticals Inc #Adjunctive Therapy #Placebo-Controlled Phase #Median Percent Change

Abstract
Full-Text
Similar Papers

Abstract

Listen

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of XEN1101 as an Adjunctive Therapy in the Treatment of Primary Generalized Tonic-Clonic Seizures (P11-1.012)

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Neurology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of XEN1101 as an Adjunctive Therapy in the Treatment of Primary Generalized Tonic-Clonic Seizures (P11-1.012)